G-BA backs J&J's Sylvant

Germany's Federal Joint Committee (G-BA) concluded that Sylvant siltuximab from Johnson & Johnson (NYSE:JNJ) provides added benefit for patients with multicentric Castleman's disease (MCD) who are HIV-negative and human herpes virus 8 (HHV-8)-negative, the drug's approved indication.

The committee said the extent of the drug's benefit could not be quantified. G-BA estimated that 130-1,460 patients could benefit from the chimeric mAb against IL-6. ...